No­var­tis’ re­cent­ly de­part­ed on­col­o­gy R&D chief is head­ed back to Dana-Far­ber and a new job in can­cer re­search

The re­volv­ing door at No­var­tis has spit out an­oth­er top ex­ec­u­tive, on­ly this one is head­ed back to a fac­ul­ty post at Dana-Far­ber Can­cer In­sti­tute and Har­vard Med­ical School.

William Sell­ers had been in charge of on­col­o­gy re­search at No­var­tis be­fore he an­nounced his “re­tire­ment” ear­li­er this year. But his 11-year stint at the No­var­tis In­sti­tutes for Bio­Med­ical Re­search was not his fi­nal turn at bat in drug re­search. His new fac­ul­ty post in­cludes re­spon­si­bil­i­ties as a se­nior ad­vis­er on ex­per­i­men­tal meds. And he’ll still be di­rect­ly en­gaged on ear­ly-stage drug de­vel­op­ment at Dana-Far­ber, where he’ll help guide a spec­trum of work that runs from tar­get val­i­da­tion to ear­ly hu­man stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.